Virology and Immunology of Hepatitis Viruses

  • Authors: Raymond T. Chung, MD; Esperance Anne Kreek Schaefer, MD, MPH (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/10/18 (What's New)

Summary

  • Therapy for HBV infection currently includes peginterferon and nucleos(t)ide analogues that inhibit HBV polymerase[Terrault 2018; EASL HBV]
  • Peginterferon alfa-2a is administered for 48 weeks and leads to a 32% chance of HBeAg seroconversion and a 3% chance of HBsAg loss[EASL HBV]
    • A subset of patients will require retreatment

Action required

Keywords: Hepatitis B, Hepatitis B-Resistance, Hepatitis B-Treatment

©2018 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.